🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Biodexa reports promising phase 1 brain cancer drug results

EditorEmilio Ghigini
Published 23/02/2024, 13:52
© Reuters.
BDRX
-

CARDIFF, United Kingdom - Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a biopharmaceutical company focusing on unmet medical needs, announced positive outcomes from its Phase 1 clinical trial of MTX110 in treating diffuse midline glioma (DMG). The trial, initiated by Columbia University Irving Medical Center, tested the safety and tolerability of MTX110 delivered directly to the brainstem using a novel method in patients with DMG.

The study used a 3+3 dose-escalating design, treating nine patients with two infusions of MTX110 seven days apart. Despite its primary goal being to assess safety, the trial noted a median overall survival of 16.5 months among participants, compared to a historical 10.0-month median survival in a similar cohort.

While one patient experienced a severe adverse event, it was deemed unrelated to the drug. These preliminary findings are expected to be presented in detail at the 21st International Symposium on Pediatric Neuro-Oncology in Philadelphia, PA, from June 28-July 2, 2024.

In addition, Biodexa provided an update on tolimidone, aimed at Type 1 diabetes treatment. A recent in vitro study conducted by a Contract Research Organization (CRO) yielded inconclusive results on beta cell proliferation. However, the company plans to proceed with an in vivo preclinical study and is preparing for a Phase IIa study set to begin recruitment later this year.

Biodexa's pipeline includes tolimidone, an oral agent for Type 1 diabetes, and MTX110 for rare/orphan brain cancers. MTX110 is a formulation of panobinostat, an HDAC inhibitor, delivered directly to tumor sites, potentially reducing systemic toxicity.

This announcement is based on a press release statement by Biodexa Pharmaceuticals PLC. The company's future plans and clinical developments are subject to various risks and uncertainties, as noted in their forward-looking statements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.